Brief: Lunit Shows Promise Of AI In Predicting Immunotherapy Response For Rare Cancer Patients At SITC 2024
Nov 8 (Reuters) - Lunit Inc 328130.KQ :
* LUNIT SHOWS PROMISE OF AI IN PREDICTING IMMUNOTHERAPY
RESPONSE
FOR RARE CANCER PATIENTS AT SITC 2024
Source text: ID:nPn2w8ZpDa
Further company coverage: 328130.KQ
(Reuters.Briefs@thomsonreuters.com)
Recent news on Lunit
See all newsBrief: Summit Therapeutics And Lunit Announce Agreement To Apply Ai-Powered Scope Io Platform For Tumor Microenvironment Analysis In Immuno-Oncology Development
Brief: Lunit Inc To Conduct Capital Increase Of 250 Billion Won
Brief: Lunit Announces Collaboration with Daiichi Sankyo on AI-Driven Biomarker Discovery
Brief: Lunit Inc - Awarded National Tender In France For Breast AI
Brief: Lunit Expands Partnership With Saudi Arabia's Largest Medical Group To Deploy Ai Chest X-Ray Solution